Entrectinib and Felbatol (Felbamate Oral Suspension)
Determining the interaction of Entrectinib and Felbatol (Felbamate Oral Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme. When a single 600 mg dose of entrectinib was administered with rifampin, a potent CYP450 3A4 inducer, entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 77%, respectively. Coadministration of entrectinib with a moderate CYP450 3A4 inducer is predicted to decrease entrectinib Cmax and AUC by 43% and 56%, respectively. Reduced therapeutic efficacy may occur. The interaction has not been studied with other, less potent inducers. MANAGEMENT: The potential for diminished pharmacologic effects of entrectinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. References "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.
Professional:MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of entrectinib, which is a substrate of the isoenzyme. When a single 600 mg dose of entrectinib was administered with rifampin, a potent CYP450 3A4 inducer, entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 77%, respectively. Coadministration of entrectinib with a moderate CYP450 3A4 inducer is predicted to decrease entrectinib Cmax and AUC by 43% and 56%, respectively. Reduced therapeutic efficacy may occur. The interaction has not been studied with other, less potent inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of entrectinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
- "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.
Generic Name: felbamate
Brand name: Felbatol
Synonyms: Felbatol
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Entrectinib-Felbatol (Felbamate Tablets)
- Entrectinib-Feldene
- Entrectinib-Felimazole
- Entrectinib-Felodipine
- Entrectinib-Fem-Cal Citrate
- Entrectinib-Femara
- Felbatol (Felbamate Oral Suspension)-Entresto
- Felbatol (Felbamate Oral Suspension)-Entyvio
- Felbatol (Felbamate Oral Suspension)-Entyvio Injection
- Felbatol (Felbamate Oral Suspension)-Enulose
- Felbatol (Felbamate Oral Suspension)-Envarsus XR
- Felbatol (Felbamate Oral Suspension)-Enzalutamide